TY - JOUR T1 - Targeting Protein Serine/Threonine Phosphatases for Drug Development JF - Molecular Pharmacology JO - Mol Pharmacol SP - 1249 LP - 1261 DO - 10.1124/mol.108.053140 VL - 75 IS - 6 AU - Jamie L. McConnell AU - Brian E. Wadzinski Y1 - 2009/06/01 UR - http://molpharm.aspetjournals.org/content/75/6/1249.abstract N2 - With the recent clinical success of drugs targeting protein kinase activity, drug discovery efforts are focusing on the role of reversible protein phosphorylation in disease states. The activity of protein phosphatases, enzymes that oppose protein kinases, can also be manipulated to alter cellular signaling for therapeutic benefits. In this review, we present protein serine/threonine phosphatases as viable therapeutic targets, discussing past successes, current challenges, and future strategies for modulating phosphatase activity. The American Society for Pharmacology and Experimental Therapeutics ER -